Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
Stocks · News reference
Akari Therapeutics to Present RNA-Splicing ADC Payload Strategy at 3rd Annual ADC Payload Summit
Akari Therapeutics announced that its Executive Director and Head of Oncology, Satyajit Mitra, will present the company's novel RNA-splicing antibody-drug conjugate (ADC) payload strategy at the upcoming 3rd Annual ADC Payload Summit.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Akari Therapeutics shares are trading higher after the company highlighted progress toward AKTX-101 Phase 1 development and growing demand for its PH1 ADC payload platform.
8-K filing — Akari Therapeutics Plc (AKTX)
Filed: 2026-10-01 AccNo: 0001493152-26-045364 Size: 289 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.
Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data demonstrating the